Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | TSPO | P30536 | 1/20 | 0.79 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.76 |
| ▸ | BRD2 | P25440 | 3/20 | 0.76 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.76 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.76 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.76 |
| ▸ | JAK2 | O60674 | 1/20 | 0.76 |
| ▸ | BRD1 | O95696 | 1/20 | 0.76 |
| ▸ | CCL2 | P13500 | 1/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.76 |
| ▸ | EP300 | Q09472 | 1/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627341 | 1.00 | BRD4 (0.89) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19627343 | 1.00 | BRD4 (0.89) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19630937 | 0.94 | BRD4 (1.00) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19630909 | 0.94 | BRD4 (1.00) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19627339 | 0.94 | BRD4 (1.00) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19627355 | 0.93 | BRD4 (0.86) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19627354 | 0.93 | BRD4 (0.86) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19627351 | 0.93 | BRD4 (0.86) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19631001 | 0.92 | BRD4 (0.88) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19627349 | 0.92 | BRD4 (0.88) | BRD4ADORA3TSPOBRDTBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210206779-A9 | CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210015929-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-20200405809-A1 | COMBINATION OF A CYCLIN DEPENDENT KINASE INHIBITOR AND A BET- BROMODOMAIN INHIBITOR | PFIZER INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180085465-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-03-29 | — | — | US | disclosed |
| US-20170333444-A1 | BROMODOMAIN INHIBITORS | TENSHA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9821068-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9770512-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9750816-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9714946-B2 | Bromodomain binding reagents and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9694084-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2017044849-A1 | CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | MDM2, STUB1, UBE3C | BRD4 641/4885ADORA3 4257/4885TSPO 2134/4885 |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | BRD4 2934/4885ADORA3 4356/4885TSPO 1185/4885 |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | BRD4 2934/4885ADORA3 4356/4885TSPO 1185/4885 |
| US-20170333444-A1 | BROMODOMAIN INHIBITORS | BRDT, BRD4, BRPF3 | BRD4 2/4885ADORA3 4519/4885TSPO 3103/4885 |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | BRD4 687/4885ADORA3 4664/4885TSPO 1408/4885 |
| US-20210206779-A9 | CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF | BRDT, BRD4, BRD3 | BRD4 2/4885ADORA3 3711/4885TSPO 1352/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | BRD4 1005/4885ADORA3 4546/4885TSPO 1301/4885 |
| US-11046954-B2 | Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses | NFATC1, GZMB, ICOS | BRD4 2934/4885ADORA3 4356/4885TSPO 1185/4885 |
| US-20210015929-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885ADORA3 4664/4885TSPO 1408/4885 |
| US-20200405809-A1 | COMBINATION OF A CYCLIN DEPENDENT KINASE INHIBITOR AND A BET- BROMODOMAIN INHIBITOR | CDK6, CDK4, BRD4 | BRD4 3/4885ADORA3 4603/4885TSPO 3170/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | BRD4 3626/4885ADORA3 4168/4885TSPO 1995/4885 |
| US-20180085465-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885ADORA3 4664/4885TSPO 1408/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885ADORA3 4664/4885TSPO 1408/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | BRD4 1683/4885ADORA3 4129/4885TSPO 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.